AGTC - Applied Genetic Technologies Corporation
| Previous Close | 3.0600 |
| Open | 3.0700 |
| Bid | 3.1000 x 900 |
| Ask | 3.1200 x 1100 |
| Day's Range | 2.9100 - 3.1850 |
| 52 Week Range | 2.2600 - 7.4800 |
| Volume | 82,028 |
| Avg. Volume | 158,082 |
| Market Cap | 56.477M |
| Beta (3Y Monthly) | 3.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings Date | Sep 26, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.42 |
- GlobeNewswire
AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss
GAINESVILLE, Fla. and CAMBRIDGE, Mass. and SAN DIEGO, Oct. 01, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human.
- Thomson Reuters StreetEvents
Edited Transcript of AGTC earnings conference call or presentation 26-Sep-19 8:30pm GMT
Q4 2019 Applied Genetic Technologies Corp Earnings Call
- Benzinga
Applied Genetic Notches Sell-Side Upgrade After Releasing Interim Study Data
Biotechnology company Applied Genetic Technologies Corp (NASDAQ: AGTC ) presented interim six-month data Thursday for the Phase 1/2 XLRP program in X-linked retinitis pigmentosa, turning BMO Capital ...
- Zacks
Applied Genetic Technologies (AGTC) Reports Q4 Loss, Lags Revenue Estimates
Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -13.73% and -42.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
AGTC Announces Financial Results and Business Update for the Fourth Quarter and Fiscal Year Ended June 30, 2019
Company announces promising topline six-month dose escalation data from its ongoing Phase 1/2 clinical trials for X-linked retinitis pigmentosa (XLRP) Preliminary three-month.
- ACCESSWIRE
Applied Genetic Technologies Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / September 26, 2019 / Applied Genetic Technologies Corp. (NASDAQ: AGTC ) will be discussing their earnings results in their 2019 Fourth Quarter Earnings to be held on September ...
- GlobeNewswire
AGTC to Present at Upcoming Conferences
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 25, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
- Zacks
Analysts Estimate Applied Genetic Technologies (AGTC) to Report a Decline in Earnings: What to Look Out for
Applied Genetic Technologies (AGTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
AGTC to Host Fourth Quarter and Fiscal Year Financial Results Conference Call and Webcast on September 26, 2019
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 18, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
- Simply Wall St.
How Many Applied Genetic Technologies Corporation (NASDAQ:AGTC) Shares Do Institutions Own?
The big shareholder groups in Applied Genetic Technologies Corporation (NASDAQ:AGTC) have power over the company...
- GlobeNewswire
Italian Achromatopsia Association Increases Global Awareness of Achromatopsia, a Rare Genetic Eye Disease, With an Expedition to Pingelap, the Island of the Color Blind
The Italian Achromatopsia Association (IAA) today announced that it is organizing a trip to Pingelap, a remote Micronesian atoll in the South Pacific, also known as the “Island of the Color Blind.” While the incidence of achromatopsia, a rare inherited retinal disease (IRD), in the general population is 1 in every 30,000 individuals, the condition is found in between 10 and 30 percent of Pingelap’s population. The trip was made possible in part by a number of sponsors, including Applied Genetic Technologies Corporation (AGTC), a biotechnology company that is committed to developing transformational genetic therapies for patients suffering from rare diseases, including achromatopsia.
- GlobeNewswire
AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 14, 2019
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 07, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
- Zacks
Alexion (ALXN) Q2 Earnings Beat Estimates, Guidance Raised
Alexion (ALXN) beats both earnings and sales estimates in the second quarter of 2019 and raises 2019 guidance.
- GlobeNewswire
AGTC Completes Enrollment of Third Group in the Dose Escalation Portion of the Achromatopsia CNGA3 Phase 1/2 Clinical Study
Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has completed enrollment of the third group in the dose escalation portion of its Phase 1/2 clinical trial evaluating the safety and efficacy of subretinal injection of (rAAV2tYF-PR1.7-hCNGA3) for the treatment of achromatopsia (ACHM) caused by mutations in the CNGA3 gene. “This achievement is another demonstration of our continued progress in the clinical development of our three product candidates for the treatment of X-linked retinitis pigmentosa and achromatopsia due to mutations in the CNGA3 or CNGB3 gene,” said Sue Washer, president and CEO of AGTC.
- Zacks
Horizon's NDA for Procysbi New Dosage Form Accepted by FDA
The FDA accepts Horizon Therapeutics' (HZNP) NDA for Procysbi (Cysteamine Bitartrate) delayed-release oral granules in packets.
- Simply Wall St.
Is Applied Genetic Technologies Corporation (NASDAQ:AGTC) Overpaying Its CEO?
Sue Washer has been the CEO of Applied Genetic Technologies Corporation (NASDAQ:AGTC) since 2002. This analysis aims...
- Zacks
Horizon Therapeutics Files BLA to FDA for Eye Disease Drug
Horizon Therapeutics (HZNP) files a BLA for teprotumumab to the FDA for the treatment of active thyroid eye disease.
- Zacks
Mirati Inks Deal with Novartis to Evaluate Tumor Candidate
Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.
- Zacks
Kadmon Initiates Dosing in Study for Systemic Sclerosis Drug
Kadmon (KDMN) doses first patient in a phase II study of KD025 for the treatment of diffuse cutaneous systemic sclerosis (SSc).
- Zacks
ObsEva Ends Recruitment in Second Uterine Fibroids Study
ObsEva (OBSV) completes patient recruitment in the second pivotal phase III study evaluating linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids.
- Zacks
Catalyst Pharma Focuses on Firdapse Launch & Label Expansion
Catalyst Pharmaceuticals (CPRX) intends to launch Firdapse and expand the label of the same.
- Zacks
Novavax (NVAX) Seeks Accelerated Approval Pathway for NanoFlu
Novavax (NVAX) seeks to use accelerated approval pathway for its influenza vaccine candidate, NanoFlu, in the United States.
- Zacks
Alnylam Presents New Data for RNAi Therapeutic Onpattro
Alnylam (ALNY) announces new results from the Global Open-Label Extension study of Onpattro at the 2019 Peripheral Nerve Society (PNS) Annual Meeting.
